Vancomycin tissue pharmacokinetics in patients with lower-limb infections via in vivo microdialysis

Journal of the American Podiatric Medical Association

Volumn 105, Issue 5, 2015, Pages 381-388

  Housman, Seth T ^a   Bhalodi, Amira A ^a   Shepard, Ashley ^a   Nugent, James ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; FOLLOW UP; HUMAN; LOWER LIMB; MALE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MICRODIALYSIS; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOWER EXTREMITY; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICRODIALYSIS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 85016925029     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/14-033     Document Type: Article

References (26)

1. NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32: 470, 2004.
2. STREIT JM, JONES RN, SADER HS, et al: Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY antimicrobial surveillance program (North America, 2001). Int J Antimicrob Agents 24: 111, 2004.
3. NAIMI TS, LEDELL KH, COMO-SABETTI K, et al: Comparison of community- and health care–associated methicillinresistant Staphylococcus aureus infection. JAMA 290: 2976, 2003.
4. OCHOA TJ, MOHR J, WANGER A, et al: Communityassociated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis 11: 966, 2005.
5. MORAN GJ, AMII RN, ABRAHAMIAN FM, et al: Methicillinresistant Staphylococcus aureus in community-acquired infections. Emerg Infect Dis 11: 928, 2005.
6. RYBAK M, LOMAESTRO B, ROTSCHAFER JC, et al: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82, 2009.
7. LODISE TP, PATEL N, LOMAESTRO BM, et al: Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49: 507, 2009.
8. LODISE TP, LOMAESTRO B, GRAVES J, et al: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52: 1330, 2008.
9. WHITENER CJ, PARK SY, BROWNE FA, et al: Vancomycinresistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 38: 1049, 2004.
10. APPELBAUM PC: Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 30: 398, 2007.
11. LODISE TP, GRAVES J, EVANS A, et al: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315, 2008.
12. PAYNE CJ, THOMSON AH, STEARNS AT, et al: Pharmacokinetics and tissue penetration of vancomycin continuous infusion as prophylaxis for vascular surgery. J Antimicrob Chemother 66: 2624, 2011.
13. SKHIRTLADZE K, HUTSCHALA D, FLECK T, et al: Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 50: 1372, 2006.
14. LODISE TP, DRUSANO GL, BUTTERFIELD JM, et al: Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother 55: 5507, 2011.
15. RICARD JD, WOLFF M, LACHERADE JC, et al: Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 44: 250, 2007.
16. LIPSKY BA, BERENDT AR, CORNIA PB, et al: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. JAPMA 103: 2, 2013.
17. KIM A, SUECOF LA, SUTHERLAND CA, et al: In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 52: 3941, 2008.
18. BULIK CC, WISKIRCHEN DE, SHEPARD A, et al: Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 54: 5209, 2010.
19. SAHRE M, SABARINATH S, GRANT M, et al: Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents 40: 51, 2012.
20. HAGIHARA M, SUTHERLAND C, NICOLAU DP: Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid. J Chromatogr Sci 51: 201, 2013.
21. MACVANE SH, HOUSMAN ST, NICOLAU DP: Assessing the impact of combination antibiotic therapy on in vitro microdialysis recoveries. Paper presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO. Abstract F-1700.
22. FARRELL DJ, CASTANHEIRA M, MENDES RE, et al: In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis 55 (suppl 3): S206, 2012.
23. JOUKHADAR C, MULLER M: Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 44: 895, 2005.
24. CRANDON JL, MACVANE SH, NICOLAU DP: Clinical laboratory based assay methodologies may underestimate and increase variability of vancomycin protein binding in patients. Pharmacotherapy 34: 203, 2014.
25. KEEL RA, CRANDON JL, NICOLAU DP: Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother 56: 3420, 2012.
26. KUTI JL, NICOLAU DP: Levofloxacin penetration into epithelial lining fluid differs between infected and uninfected patients. Paper presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA. Abstract A-1964.